Partnering

Bentley continues to strengthen its intellectual property portfolio across the Company’s broader drug delivery business as additional applications of CPE-215 are pursued. The technology, validated with the marketed product Testim and very promising data for Nasulin, has broad applications to the universe of therapeutic peptides where a non-injectable formulation would provide considerable market potential.

Access to Bentley’s permeation enhancement technology with the key excipient, CPE-215, is currently being offered to pharmaceutical and biotechnology companies whose products could potentially benefit from its permeation enhancement properties – either as new product launches, as part of product lifecycle management or line-extension strategies. Our strategy includes out-licensing of our CPE-215 permeation technology and in-licensing of drug targets.

If you would like to explore a possible partnership with Bentley Pharmaceuticals, please contact:

David C. Brush
Vice President of Business Development and Strategic Planning
Bentley Pharmaceuticals, Inc.
Bentley Park, 2 Holland Way
Exeter, NH 03833
(603) 658-6100
email: dbrush@bentleypharm.com